<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515812</url>
  </required_header>
  <id_info>
    <org_study_id>10-075</org_study_id>
    <nct_id>NCT02515812</nct_id>
  </id_info>
  <brief_title>Comparative Study of Cardiac Adrenergic Function Explored by I-123-MIBG and CZT Camera (D-SPECT) Versus Anger Camera in Patients With Heart Failure</brief_title>
  <acronym>ADRECARD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiological examination constitute one of the major directions in nuclear medicine for&#xD;
      detection of myocardial ischemia in patients suspected of coronary disease. In Caen, they&#xD;
      constitute 20% of the activity of nuclear medicine. Systolic heart failure (HF) ischemic or&#xD;
      nonischemic origin represents a new area of activity of the nuclear cardiology. This is HF&#xD;
      stratification study based on cardiac adrenergic function after injection of a tracer:&#xD;
      I-123-MIBG. The team Caen nuclear cardiology is one of two teams recognized internationally&#xD;
      in the field of evaluating the cardiac sympathetic innervation in cardiomyopathies. Numerous&#xD;
      publications from 1992 to the present day have reported encouraging results for the daily use&#xD;
      of this tracer in the evaluation of patients with LV dysfunction IC. Recently, interest in&#xD;
      using the MIBG has been shown as a prognostic marker of HF in a prospective study of 961&#xD;
      patients. Typically, the camera used was an Anger camera with collimating Nai standard called&#xD;
      parallel holes.&#xD;
&#xD;
      The main objective is to validate the measurements of cardiac adrenergic function evaluated&#xD;
      by cardiopulmonary mediastinal reports and sympathetic innervation scores VG after injection&#xD;
      of I-123-MIBG in 80 patients with heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SRSI (summed rest score innervation)</measure>
    <time_frame>4 hours after I-123-MIBG perfusion</time_frame>
    <description>with CZT camera and Anger camera</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SRS (summed rest score)</measure>
    <time_frame>4 hours after I-123-MIBG perfusion</time_frame>
    <description>with CZT camera and Anger camera</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Adrenergic Function Explorations with CZT camera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I-123-MIBG and CZT Camera (D-SPECT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adrenergic Function Explorations with Anger camera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I-123-MIBG and Anger Camera</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-123-MIBG</intervention_name>
    <arm_group_label>Adrenergic Function Explorations with Anger camera</arm_group_label>
    <arm_group_label>Adrenergic Function Explorations with CZT camera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CZT Camera (D-SPECT)</intervention_name>
    <arm_group_label>Adrenergic Function Explorations with CZT camera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anger Camera</intervention_name>
    <arm_group_label>Adrenergic Function Explorations with Anger camera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18 years (except major patients under guardianship)&#xD;
&#xD;
          -  patient who signed the consent form&#xD;
&#xD;
          -  written and spoken French&#xD;
&#xD;
          -  Beneficiaries of the social security system&#xD;
&#xD;
          -  Stable heart failure with LV dysfunction (&lt;45%) of ischemic or nonischemic origin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a recent history (&lt;21 days) acute coronary failure (myocardial&#xD;
             infarction, unstable angina)&#xD;
&#xD;
          -  Patients with severe extra-cardiac disease may interfere with treatment decisions&#xD;
             (cancer, severe hepatic or renal impairment)&#xD;
&#xD;
          -  Major patients under guardianship&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women in age and condition of childbearing&#xD;
&#xD;
          -  Patients unable to understand the purpose of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Médecine Nucléaire -CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>August 2, 2015</last_update_submitted>
  <last_update_submitted_qc>August 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

